Singapore's Biomedical Sciences Industry Tripled Output In Nine Years
This article was originally published in PharmAsia News
Singapore's Economic Development Board estimates the output of the nation's biomedical sciences industry is worth about $15.1 billion, three times its value at the beginning of the decade
You may also be interested in...
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.